Survival and prognostic factors at time of diagnosis in high-grade appendicular osteosarcoma: a 21 year single institution evaluation from east Denmark

References

• Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer. 2012;131:E508–E517.
   PubMed Web of Science ®Google Scholar
• Aggerholm-Pedersen N, Maretty-Nielsen K, Keller J, et al. The importance of standardized treatment in high-grade osteosarcoma: 30 years of experience from a hospital-based database. Acta Oncol. 2015;54:17–24.
   PubMed Web of Science ®Google Scholar
• Zaikova O, Sundby Hall K, Styring E, et al. Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia–SSG Central Register 25 years' experience. J Surg Oncol. 2015;112:853–860.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–1543.
   PubMed Web of Science ®Google Scholar
• Berlanga P, Canete A, Diaz R, et al. Presentation and long-term outcome of high-grade osteosarcoma: a single-institution experience. J Pediatr Hematol Oncol. 2015;37:e272–e277.
   PubMed Web of Science ®Google Scholar
• Durnali A, Alkis N, Cangur S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.
   PubMed Web of Science ®Google Scholar
• Whelan JS, Jinks RC, McTiernan A, et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol. 2012;23:1607–1616.
   PubMed Web of Science ®Google Scholar
• Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am. 2016;47:283–292.
   PubMed Web of Science ®Google Scholar
• Berner K, Hall KS, Monge OR, et al. Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient. Sarcoma. 2015;2015:516843.
   PubMedGoogle Scholar
• Venkatramani R, Murray J, Helman L, et al. Risk-based therapy for localized osteosarcoma. Pediatr Blood Cancer. 2016;63:412–417.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. The Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–56.
   PubMedGoogle Scholar
• Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance PEGylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279–2287.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Hung GY, Yen HJ, Yen CC, et al. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival. Ann Surg Oncol. 2015;22:1080–1087.
   PubMed Web of Science ®Google Scholar
• Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–532.
   PubMed Web of Science ®Google Scholar
• Meazza C, Luksch R, Daolio P, et al. Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents. Med Oncol. 2014;31:875.
   PubMed Web of Science ®Google Scholar
• Kim SH, Shin KH, Park EH, et al. A new relative tumor sizing method in epi-metaphyseal osteosarcoma. BMC Cancer. 2015;15:284.
   PubMed Web of Science ®Google Scholar
• Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol. 2014;21:263–268.
   PubMed Web of Science ®Google Scholar
• Sun L, Li Y, Zhang J, et al. Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: a systemic review and meta-analysis of cohort studies. J Orthop Res. 2015;33:131–139.
   PubMed Web of Science ®Google Scholar
• Cates JM. Pathologic fracture a poor prognostic factor in osteosarcoma: Misleading conclusions from meta-analyses? Eur J Surg Oncol. 2016;42:883–888.
   PubMed Web of Science ®Google Scholar
• Min D, Lin F, Shen Z, et al. Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy. Asia-Pac J Clin Oncol. 2013;9:71–79.
   PubMed Web of Science ®Google Scholar
• Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26:407–414.
   PubMed Web of Science ®Google Scholar